CN105044181A - 一种用于心境障碍辅助诊断的丝网印刷电极 - Google Patents
一种用于心境障碍辅助诊断的丝网印刷电极 Download PDFInfo
- Publication number
- CN105044181A CN105044181A CN201510382262.3A CN201510382262A CN105044181A CN 105044181 A CN105044181 A CN 105044181A CN 201510382262 A CN201510382262 A CN 201510382262A CN 105044181 A CN105044181 A CN 105044181A
- Authority
- CN
- China
- Prior art keywords
- electrode
- carbon
- screen printing
- auxiliary diagnosis
- mood disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 19
- 238000007650 screen-printing Methods 0.000 title claims abstract description 18
- 208000019022 Mood disease Diseases 0.000 title claims abstract description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 64
- 239000012528 membrane Substances 0.000 claims abstract description 24
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 21
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims abstract description 18
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims abstract description 18
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004544 cortisone Drugs 0.000 claims abstract description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 14
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000010931 gold Substances 0.000 claims abstract description 11
- 229910052737 gold Inorganic materials 0.000 claims abstract description 11
- 239000002048 multi walled nanotube Substances 0.000 claims abstract description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 7
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 7
- 229960004853 betadex Drugs 0.000 claims abstract description 7
- 229960003638 dopamine Drugs 0.000 claims abstract description 7
- 238000001704 evaporation Methods 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000000758 substrate Substances 0.000 claims abstract description 7
- 229910021607 Silver chloride Inorganic materials 0.000 claims abstract description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 5
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims abstract description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 229920000557 Nafion® Polymers 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 239000000084 colloidal system Substances 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000004020 conductor Substances 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000002964 excitative effect Effects 0.000 abstract 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000010422 painting Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 15
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 15
- 229960002748 norepinephrine Drugs 0.000 description 15
- 229940076279 serotonin Drugs 0.000 description 14
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 238000002484 cyclic voltammetry Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229920000831 ionic polymer Polymers 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- -1 beta cyclodextrin compound Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004365 square wave voltammetry Methods 0.000 description 2
- 108010050939 thrombocytin Proteins 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001903 differential pulse voltammetry Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009422 external insulation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明属于医疗辅助设备领域，具体是一种用于心境障碍辅助诊断的丝网印刷电极，所述电极的基片上印制有三个电极，分别为一个金电极、一个碳电极和一个Ag/AgCl电极，各电极对应连接有一根电极引线；碳电极表面涂覆有一层敏感膜，该敏感膜是将质量体积百分数为0.01%～10%的多壁碳纳米管（MWNTs——Multi-walled？carbon？nanotubes）、0.01%～10%的多巴胺聚合物、0.01%～10%的β环糊精的混合物的悬液涂覆在碳电极表面，低温蒸发溶剂得到。本发明的有益效果在于：解决了传感器稳定性、灵敏度和选择性不足的问题，并可测定5-HT、NE、可的松、单胺递质。
Description
技术领域
本发明属于医疗辅助设备领域，具体是一种用于心境障碍辅助诊断的丝网印刷电极。
背景技术
5-羟色胺是一种能产生愉悦情绪的信使，几乎影响到大脑活动的每一个方面：从调节情绪、精力、记忆力到塑造人生观。抗抑郁药如盐酸氟西汀就是通过提高脑内5-羟色胺水平而起作用的。5-羟色胺水平较低的人群更容易发生抑郁、冲动行为、酗酒、自杀、攻击及暴力行为。科学家们甚至通过改变实验动物脑内5-羟色胺的水平使他们更具有攻击性。
据研究显示，60岁与30岁的人相比，大脑中5-羟色胺特异受体的数目已减少了60%。由于5-羟色胺的效力下降，随年龄增长患抑郁症的可能性增加。另外，5-羟色胺还能增强记忆力，并能保护神经元免受“兴奋神经毒素”的损害，所以充足的5-羟色胺确实能在老化过程中防止脑损害发生。因此，对于心境障碍或抑郁患者，长期且稳定监控患者体内的5-羟色胺水平就显得十分必要。
去甲肾上腺素（NE）是肾上腺素去掉N-甲基后形成的物质，在化学结构上也属于儿茶酚胺，它既是一种神经递质，主要由交感节后神经元和脑内肾上腺素能神经末梢合成和分泌，是后者释放的主要递质，也是一种激素，由肾上腺髓质合成和分泌。某些抑郁的发生与儿茶酚胺，尤其是NE在重要脑区的绝对或相对缺乏有关，而躁狂则与儿茶酚胺过多有关。因此，连续监测心境障碍患者的NE水平有助于类似疾病的辅助诊断和治疗。
人体中存在着各种履行不同使命的激素。抑郁症及心理障碍的发病与体内可的松含量的变化密切相关。研究表明，在抑郁症患者身上，紧张荷尔蒙可的松明显长期超量，但却找不到外界的影响，只有在抑郁症改善之后，可的松的水平才相应下降。因此，对可的松水平的监测可有效了解病人的心理状况，提前做出诊断。
单胺递质是人体内重要的神经传递物质，它参与许多生命疾病过程，研究表明抑郁症、头痛、精神疾病等的发生与单胺水平有着密切关联。目前临床精神类疾病的诊断，主要根据病人的病史和临床表现，通过量表或心理诊断完成，如汉密顿抑郁量表（HAMD），其准确率不高，易误诊。寻找快速，准确的单胺递质测定方法，能够实现临床快速检验，具有重要的医学意义。
现行5-HT、NE、可的松、单胺递质等大部分物质浓度测定方法主要为光谱法、高效液相色谱法、质谱法、核磁共振等，方法繁琐、样本需求量大、耗时长，基本无法用于临床诊断，也无法普及用于社区医院和家庭自主测定。因此，开发出高灵敏度、高选择性的测定多种物质的电化学传感器成为亟待解决的问题。
电分析方法具有灵敏度高、选择性好，响应时间短等优点被广泛应用于此类生命物质的直接检测。目前应用于微量元素测定的电极已有许多，多为柱状玻碳电极，成本高，多次使用后需要重新修饰，面临重现性问题。
发明内容
本发明的目的在于克服上述不足，提供一种用于心境障碍辅助诊断的丝网印刷电极，其解决了传感器稳定性、灵敏度和选择性不足的问题，并可测定5-HT、NE、可的松、单胺递质。
为实现上述技术目的，本发明提供的方案是：一种用于心境障碍辅助诊断的丝网印刷电极，所述电极的基片上印制有三个电极，分别为一个金电极、一个碳电极和一个Ag/AgCl电极，各电极对应连接有一根电极引线；碳电极表面涂覆有一层敏感膜，该敏感膜是将质量体积百分数为0.01%～10%的多壁碳纳米管（MWNTs——Multi-walledcarbonnanotubes）、0.01%～10%的多巴胺聚合物、0.01%～10%的β环糊精的混合物的悬液涂覆在碳电极表面，低温蒸发溶剂得到。
而且，所述碳电极是由含有质量体积百分数为0.01%～10%的胶体金颗粒、0.01%～10%的Nafion的碳浆制得。
本发明还提供前述一种用于心境障碍辅助诊断的丝网印刷电极的用途，其用于抑郁辅助诊断中，对生物样品中的5-HT（即5-hydroxytryptamine，中文名5-羟色胺，又名血清素）、NE（去甲肾上腺素）、可的松的测定，生物样品包括血液、唾液、头发。
本发明的有益效果在于：在碳电极表面覆盖的一层敏感膜，不仅可进一步加速电子传递及催化活性，提高该电极对微量元素的响应灵敏度，更有利于传感器的稳定保存，减少传感器之间的个体差异；采用的丝网印刷电极可实现批次制作，即用即抛，价格低廉，并且采样量少，样品无需复杂前处理，非常适用于临床、家庭方便、快捷检测。
附图说明
图1为本发明丝网印刷电极的结构示意图。
图2为本发明对5-HT（五羟色胺）的选择性响应图。
图3为本发明对可的松（cortisone）的选择性响应图。
图4为本发明对血样中NE（去甲肾上腺素）和5-HT（五羟色胺）和可的松（cortisone）选择性响应图。
具体实施方式
下面结合附图及实施例对本发明作进一步说明。
本实施例提供一种用于心境障碍辅助诊断的丝网印刷电极，如图1所示，包括印制电极的基片1、碳电极2、金电极3、Ag/AgCl电极4和基片上印制的外部绝缘层6，各电极对应连接有一根电极引线5。
碳电极2表面涂覆有一层敏感膜，该敏感膜是将质量体积百分数为0.01%～10%的多壁碳纳米管（MWNTs——Multi-walledcarbonnanotubes）、0.01%～10%的多巴胺聚合物、0.01%～10%的β环糊精的混合物的悬液涂覆在碳电极表面，低温蒸发溶剂得到。Nafion是阳离子交换剂的典型代表，溶于有机溶剂，浇铸在电极表面形成一层稳定的修饰膜。对有机阳离子的选择性特别高。
进一步的，上述碳电极是由含有质量体积百分数为0.01%～10%的胶体金颗粒、0.01%～10%的Nafion的碳浆制得。
本实施例还提供前述一种用于心境障碍辅助诊断的丝网印刷电极的用途，其用于抑郁辅助诊断中，对生物样品中的5-HT（即5-hydroxytryptamine，中文名5-羟色胺，又名血清素）、NE（去甲肾上腺素）、可的松的测定，生物样品包括血液、唾液、头发。
实施例1：根据上述方法制作丝网印刷电极，制作碳电极制作碳电极（c）的碳浆中含有质量体积百分数为2%的胶体金颗粒和2%的Nafion。待印制的电极烘干后，于碳电极表面涂覆一层敏感膜，敏感膜由下法得到：将为质量体积百分数为4%多壁碳纳米管、0.5%多巴胺聚合物、0.1%β环糊精复合物的悬液涂覆在碳电极表面，低温蒸发溶剂得到敏感膜。
在pH6.8~8.4生理缓冲液中，5-HT通过离子选择性膜可以选择性地到达传感器的敏感单元。本品发明对5-HT电子催化性能和离子聚合物膜的选择性富集作用有机结合起来，实现了5-HT高灵敏搞选择测定，如图2。
测定条件：测定介质0.1mol/L的磷酸盐缓冲液（pH7.0），富集时间为5分钟。
测定方法：1）循环伏安法，电位扫描范围0.2～1.0V，扫描速度100mv/s；2）微分脉冲伏安法，电位扫描范围0.2～1.0V，参数设置：脉冲振幅0.05V；脉冲时间40ms，电位增量为0.004V。测定结果如图2所示。
结论：本发明可用于生物样本中5-HT的测定。
实施例2：根据上述方法制作丝网印刷电极，制作碳电极制作碳电极2的碳浆中含有质量体积百分数为6.5%的胶体金颗粒和5%的Nafion。待印制的电极烘干后，于碳电极表面涂覆一层敏感膜，敏感膜由下法得到：将质量体积百分数为2.5%多壁碳纳米管、2%多巴胺聚合物、0.5%β环糊精复合物的悬液涂覆在碳电极表面，低温蒸发溶剂得到敏感膜。
在pH6.8~8.4生理缓冲液中，可的松通过离子选择性膜可以选择性地到达传感器的敏感单元。本品发明对可的松的电子催化性能和离子聚合物膜的选择性富集作用有机结合起来，实现了可的松的高灵敏搞选择测定。
测定条件：测定介质0.1mol/L的磷酸盐缓冲液（pH7.0），富集时间为4分钟。
测定方法：1）循环伏安法，电位扫描范围-0.2～0.8V，扫描速度100mv/s；2）方波伏安法，电位扫描范围-0.2～0.8V，参数设置：方波振幅0.025V；方波频率：10Hz；脉冲时间40ms，电位增量为0.006V。响应结果如图3所示。
结论：本发明可用于生物样本中可的松的测定。
实施例3：首先选取基片清洁并干燥耐热，然后印刷电极引线，接着烘干基片，印制含质量百分比为8%胶体金颗粒、8%Nafion碳浆的碳电极并烘干，印制Ag/AgCl电极并烘干和印制金电极并烘干，最后采用绝缘浆印制绝缘层并固化。取质量百分数为0.5%多壁碳纳米管、8%多巴胺聚合物、1%β环糊精液涂覆在碳电极表面，低温蒸发溶剂得到敏感膜。
在pH6.8~8.4生理缓冲液中，不同单胺递质通过离子选择性膜可以选择性地到达传感器的敏感单元。本品发明对去甲肾上腺素（NE）、五羟色胺（5-HT）的电子催化性能和离子聚合物膜的选择性富集作用有机结合起来，实现了5-HT、NE高灵敏度选择测定，如图4。
测定条件：测定介质0.05mol/L的Tris-HCl缓冲液（pH7.5），富集时间为6分钟。
测定方法：1）循环伏安法，电位扫描范围-0.2～0.8V，扫描速度100mv/s；2）方波伏安法，电位扫描范围-0.2～0.8V，参数设置：方波振幅0.025V；方波频率：20Hz；脉冲时间40ms，电位增量为0.006V。
结论：本专利发明的丝网印刷电极，可用于生物样品中单胺递质的测定。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进或变形，这些改进或变形也应视为本发明的保护范围。
Claims (3)
1.一种用于心境障碍辅助诊断的丝网印刷电极，其特征在于：所述电极的基片上印制有三个电极，分别为一个金电极、一个碳电极和一个Ag/AgCl电极，各电极对应连接有一根电极引线；碳电极表面涂覆有一层敏感膜，该敏感膜是将质量体积百分数为0.01%～10%的多壁碳纳米管、0.01%～10%的多巴胺聚合物、0.01%～10%的β环糊精的混合物的悬液涂覆在碳电极表面，低温蒸发溶剂得到。
2.根据权利要求1所述的一种用于心境障碍辅助诊断的丝网印刷电极，其特征在于：所述碳电极是由含有质量体积百分数为0.01%～10%的胶体金颗粒、0.01%～10%的Nafion的碳浆制得。
3.如权利要求1或2所述的一种用于心境障碍辅助诊断的丝网印刷电极的用途，其特征在于：用于抑郁辅助诊断中，对生物样品中的5-HT、NE、可的松的测定，生物样品包括血液、唾液、头发。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510382262.3A CN105044181B (zh) | 2015-07-03 | 2015-07-03 | 一种用于心境障碍辅助诊断的丝网印刷电极 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510382262.3A CN105044181B (zh) | 2015-07-03 | 2015-07-03 | 一种用于心境障碍辅助诊断的丝网印刷电极 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105044181A true CN105044181A (zh) | 2015-11-11 |
| CN105044181B CN105044181B (zh) | 2017-10-24 |
Family
ID=54450891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510382262.3A Active CN105044181B (zh) | 2015-07-03 | 2015-07-03 | 一种用于心境障碍辅助诊断的丝网印刷电极 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105044181B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106769965A (zh) * | 2016-12-12 | 2017-05-31 | 盐城工学院 | 一种利用5‑羟色胺‑金纳米粒子检测多巴胺的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101639457A (zh) * | 2009-08-06 | 2010-02-03 | 武汉思达创新医药科技有限公司 | 丝网印刷电极在测定5-羟色胺中的应用 |
| CN104458852A (zh) * | 2014-12-10 | 2015-03-25 | 武汉华纳联合药业有限公司 | 一种丝网印刷电极及应用 |
| CN104502432A (zh) * | 2014-12-22 | 2015-04-08 | 武汉中智博大科技有限公司 | 一种敏感膜及含有该敏感膜的丝网印刷电极及其应用 |
-
2015
- 2015-07-03 CN CN201510382262.3A patent/CN105044181B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101639457A (zh) * | 2009-08-06 | 2010-02-03 | 武汉思达创新医药科技有限公司 | 丝网印刷电极在测定5-羟色胺中的应用 |
| CN104458852A (zh) * | 2014-12-10 | 2015-03-25 | 武汉华纳联合药业有限公司 | 一种丝网印刷电极及应用 |
| CN104502432A (zh) * | 2014-12-22 | 2015-04-08 | 武汉中智博大科技有限公司 | 一种敏感膜及含有该敏感膜的丝网印刷电极及其应用 |
Non-Patent Citations (3)
| Title |
|---|
| G. ALARCON-ANGELES, B. PE-LOPEZ, M. PALOMAR-PARDAVE ET.AL: "Enhanced host–guest electrochemical recognition of dopamine using cyclodextrin in the presence of carbon nanotubes", 《CARBON》 * |
| M. PALOMAR-PARDAVÉ, G. ALARCÓN-áNGELES, S. CORONA AVENDAñO ET.AL: "Study on the Supramolecular Interaction of Dopamine With Carbon Nanotubes and β-Cyclodextrin Immovilized over a Carbon Paste Electrode", 《ECS TRANSACTIONS》 * |
| 李云龙, 苏招红, 陈超, 孟越, 谢青季: "聚多巴胺／多壁碳纳米管／玻璃碳电极上多巴胺的电分析", 《应用化学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106769965A (zh) * | 2016-12-12 | 2017-05-31 | 盐城工学院 | 一种利用5‑羟色胺‑金纳米粒子检测多巴胺的方法 |
| CN106769965B (zh) * | 2016-12-12 | 2019-07-19 | 盐城工学院 | 一种利用5-羟色胺-金纳米粒子检测多巴胺的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105044181B (zh) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raj et al. | Graphene/conducting polymer nano-composite loaded screen printed carbon sensor for simultaneous determination of dopamine and 5-hydroxytryptamine | |
| Shetti et al. | A novel biosensor based on graphene oxide-nanoclay hybrid electrode for the detection of Theophylline for healthcare applications | |
| Jackowska et al. | New trends in the electrochemical sensing of dopamine | |
| Jacobs et al. | High temporal resolution measurements of dopamine with carbon nanotube yarn microelectrodes | |
| Atta et al. | Simultaneous determination of paracetamol and neurotransmitters in biological fluids using a carbon paste sensor modified with gold nanoparticles | |
| Babaei et al. | A selective simultaneous determination of levodopa and serotonin using a glassy carbon electrode modified with multiwalled carbon nanotube/chitosan composite | |
| Shahrokhian et al. | Application of pyrolytic graphite modified with nano-diamond/graphite film for simultaneous voltammetric determination of epinephrine and uric acid in the presence of ascorbic acid | |
| Sheikh‐Mohseni et al. | Nanostructured conducting polymer/copper oxide as a modifier for fabrication of L‐DOPA and uric acid electrochemical sensor | |
| Chasta et al. | Molecularly imprinted sensor based on o-aminophenol for the selective determination of norepinephrine in pharmaceutical and biological samples | |
| Johnson et al. | Measurement of basal neurotransmitter levels using convolution-based nonfaradaic current removal | |
| Samba et al. | Application of PEDOT‐CNT Microelectrodes for Neurotransmitter Sensing | |
| Taei et al. | Simultaneous determination of cysteine, uric acid and tyrosine using Au-nanoparticles/poly (E)-4-(p-tolyldiazenyl) benzene-1, 2, 3-triol film modified glassy carbon electrode | |
| CN106404863B (zh) | 一种活体在线检测植物玉米素的微电极生物传感器及其应用 | |
| Shahrokhian et al. | Gold Electrode Modified with Self‐Assembled Monolayer of Cysteamine‐Functionalized MWCNT and Its Application in Simultaneous Determination of Dopamine and Uric Acid | |
| Gorduk | Differential pulse voltammetric determination of serotonin using an acid-activated multiwalled carbon nanotube–over-oxidized poly (3, 4-ethylenedioxythiophene) modified pencil graphite electrode | |
| He et al. | Voltammetric determination of sulfonamides with a modified glassy carbon electrode using carboxyl multiwalled carbon nanotubes | |
| Song et al. | Design and preparation of open circuit potential biosensor for in vitro and in vivo glucose monitoring | |
| CN101639457A (zh) | 丝网印刷电极在测定5-羟色胺中的应用 | |
| Chen et al. | Highly sensitive temperature‐responsive sensor based on PS‐PDEA‐PS/C60‐MWCNTs for reversible switch detection of catechol | |
| Gholivand et al. | Simultaneous voltammetric determination of theophylline and guaifenesin using a multiwalled carbon nanotube‐ionic liquid modified glassy carbon electrode | |
| Ghanbari et al. | An electrochemical sensor based on Pt nanoparticles decorated over-oxidized polypyrrole/reduced graphene oxide nanocomposite for simultaneous determination of two neurotransmitters dopamine and 5-Hydroxy tryptamine in the presence of ascorbic acid | |
| Hendawy et al. | A Zirconium Oxide Nanoparticle Modified Screen‐printed Electrode for Anodic Stripping Determination of Daclatasvir Dihydrochloride | |
| Song et al. | Carbon-based electrochemical sensors for in vivo and in vitro neurotransmitter detection | |
| Zeng et al. | Simultaneous detection of norepinephrine and 5-hydroxytryptophan using poly-alizarin/multi-walled carbon nanotubes-graphene modified carbon fiber microelectrode array sensor | |
| Borazjani et al. | Betamethasone‐based chiral electrochemical sensor coupled to chemometric methods for determination of mandelic acid enantiomers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151221 Address after: 430000 Hubei city in Wuhan Province Economic Development Zone No. 6 Jiang Road, Jianghan District 5 floor C District Applicant after: WUHAN WORDNER UNITED PHARMACEUTICAL Co.,Ltd. Address before: 430000, Hubei Province, Wuchang District, East Lake Road, Wuhan province new Bay Village 26-1-702 Applicant before: Du Sida |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231219 Address after: 430024, 5th Floor, Zone C, No. 6 Jiangwang Road, Economic Development Zone, Jianghan District, Wuhan City, Hubei Province Patentee after: WUHAN WORDNER UNITED PHARMACEUTICAL Co.,Ltd. Patentee after: WUHAN University Address before: Zone C, 5th Floor, No. 6 Jiangwang Road, Economic Development Zone, Jianghan District, Wuhan City Patentee before: WUHAN WORDNER UNITED PHARMACEUTICAL Co.,Ltd. |